Retinal diseases are at the forefront of a quiet revolution in the realm of ophthalmology. Gene therapy, once a distant dream, is now emerging as a beacon of hope for millions affected by these ...

Key market opportunities lie in AAV gene therapy advancements for hereditary retinal diseases. Future prospects include combination with CRISPR for precise genome editing, novel delivery platforms, ...

Gene therapy with voretigene neparvovec-rzyl partially restores geniculostriate pathway function in LCA2 patients, improving visual processing. Initial LCA2 pathology shifts visual processing from the ...

Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the company’s eye disease gene therapy. The candidate improved the structure and function of the ...

Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or ...

Nanoscope Therapeutics is back with more data assessing its gene therapy that uses light-sensitive molecules to treat retinal disease. With data demonstrating vision improvement in hand, the biotech ...

Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional ...

Gene therapy emerges as a transformative force in ophthalmology, offering renewed hope for patients with retinal diseases. This innovative approach targets both inherited and acquired conditions, ...

A single dose of EDIT-101, a CRISPR-associated protein 9 (Cas9)-based gene-editing therapy, appears safe and improves vision and sensitivity to light in patients with retinal disease associated with ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...

"This pivotal work from the group at the University of Iowa has shown that one of the most severe degenerative diseases affecting the retina, juvenile NCL, may also be treatable with gene therapy." ...

Opus Genetics, Inc., a clinical-stage biotechnology company focusing on gene therapies for inherited retinal diseases, announced upcoming presentations at various scientific conferences in May 2025.